The Market Reports

Synopsis
The global market for Favipiravir was estimated to be worth US$ 40.3 million in 2024 and is forecast to a readjusted size of US$ 7.3 million by 2031 with a CAGR of -22.0% during the forecast period 2025-2031.
Favipiravir, sold under the brand name Avigan, is an antiviral medication used to treat influenza in Japan. It is also being studied to treat a number of other viral infections. Like the experimental antiviral drugs (T-1105 and T-1106), it is a pyrazinecarboxamide derivative. It is being developed and manufactured by Toyama Chemical (Fujifilm group) and was approved for medical use in Japan in 2014. In 2016, Fujifilm licensend API for it to Zhejiang Hisun Pharmaceutical Co. of China. It became a generic drug in 2019.
The Favipiravir market has witnessed accelerated growth primarily due to the global urgency for effective antiviral therapies during outbreaks such as COVID-19. Its broad-spectrum activity against RNA viruses makes it a valuable candidate in pandemic preparedness plans. Several countries have approved Favipiravir for emergency or conditional use during viral outbreaks, boosting its visibility and adoption. Moreover, the drug's oral administration route offers ease of distribution and use, particularly in low-resource settings where intravenous treatments are less feasible. Continued investment in antiviral drug research, government stockpiling programs, and the rising incidence of emerging infectious diseases are expected to sustain demand for Favipiravir and similar oral antivirals in the foreseeable future.
Despite its potential, the Favipiravir market faces significant challenges. Clinical data regarding its efficacy for diseases beyond influenza, especially COVID-19, remains mixed, which has led to varied regulatory responses across different countries. Concerns over side effects such as teratogenicity limit its use among certain patient groups, particularly pregnant women. Additionally, the presence of more effective or better-studied antiviral drugs—like remdesivir, molnupiravir, and Paxlovid—creates intense competition in the antiviral space. Intellectual property issues and varying manufacturing standards across countries also affect the consistency of Favipiravir supply and global acceptance, complicating its market expansion.
In the global Favipiravir market, ChemRar Group, Glenmark, Fujifilm, Dr. Reddy, R-Pharma are the key players. The global 5 Largest Favipiravir Players account for 70% market share by revenue. India hold a key market revenue share of the Favipiravir market which account for 73%. The classification of Favipiravir includes Brand Drug and Generic Drug. Brand Drug accounted for a share of 16% in the global Favipiravir market.
This report aims to provide a comprehensive presentation of the global market for Favipiravir, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Favipiravir by region & country, by Type, and by Application.
This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Favipiravir cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.
The Favipiravir market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Favipiravir.
Market Segmentation
By Company
ChemRar Group
Glenmark
Fujifilm
Dr. Reddy
R-Pharma
Cipla
Lupin
Sun Pharma
Hisun Pharm
Segment by Type
Brand Drug
Generic Drug
Segment by Application
Influenza Viruses
COVID-19
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Favipiravir manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Favipiravir in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Favipiravir in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Index